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Abstract. Notch-3 is a receptor of the Notch signaling pathway 
and plays an important role in regulating self-renewal, differ-
entiation and apoptosis in cancer cells. Overexpression of 
Notch-3 has been proved to be associated with resistance to 
gemcitabine (GEM) and poor patient prognosis for various 
malignant tumors. In the present study, two non-small cell 
lung cancer (NSCLC) cell lines, H1299 and A549, were 
induced with GEM for two months and then were treated 
with various concentrations of a Notch signaling blocker, 
N-[N???????????????????????????????????S-phenylglycine t-butyl 
ester (DAPT), with the goal of reducing expression of Notch intra-
cellular domain 3 (NICD3). Both cell lines were subsequently 
treated with either DAPT or DAPT combined with GEM and 
then viability, apoptosis, colony formation and cell count assays 
were performed. DAPT treatment effectively downregulated the 
expression of NICD3 in both cell lines. DAPT combined with 
?????????????????????????????????????????????????????????????
in both cell lines, while increasing the percentage of apoptotic 
cells, compared with GEM alone. In the clonogenicity assays, 
the combination of DAPT and GEM led to a decrease in clone 
?????????????????????????????????????????????????????????????
A549 cells compared to treatment with DAPT or GEM alone. 
Meanwhile, levels of the apoptosis-related proteins, Bcl-2 and 
Bax, were found to be affected by the various treatments. Thus 
Notch-3 appears to be a promising target for gene therapy and 
DAPT is able to mediate a strong antitumor effect in NSCLC 
cells that overexpress Notch-3. Further studies of a combined 
treatment regimen with DAPT and GEM are warranted and may 
?????????????????????????????????????????????????????????????
patients.
Introduction
Lung cancer generally has a poor prognosis and it remains the 
leading cause of cancer-related deaths worldwide (1). Non-small 
cell lung cancer (NSCLC) represents approximately 85% of 
all newly diagnosed lung cancer cases (2). Currently, chemo-
therapy with cytotoxic agents is used for the treatment of lung 
?????????????????????????????????????????????????????????????
in the availability of targeted molecules for the inhibition of 
critical pathways in NSCLC, such as the targeting of epidermal 
growth factor receptor (EGFR) by afatinib (4). However, the 
5-year survival rate for lung cancer still remains very low.
Gemcitabine (GEM) is a type of deoxycytidine analogue 
that has exhibited strong antitumor activity (5) and has been 
widely approved for the treatment of advanced lung cancer, 
pancreatic cancer and ovarian cancer (6). However, some 
studies have demonstrated that GEM resistance often limits 
??????????????????????????????????????????????????????????
are needed. Considering the advances that have been made in 
the development of targeted therapies, a better understanding 
of lung cancer cell biology is needed to facilitate further 
advances (8,9).
Notch is a protein that plays an important role in embryo-
genesis and organogenesis by regulating cell proliferation 
and differentiation (10). This transmembrane heterodimeric 
receptor has four distinct forms (Notch1-4) in both rodents 
and humans. In particular, Notch-3 is a receptor of the Notch 
signaling pathway and it plays an important role in regu-
lating self-renewal, differentiation and apoptosis in cancer 
cells. Consequently, it represents a promising target for the 
????????????????????????????????????????????????????? 
?????????????????????????????
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development of novel therapies for the treatment of aggressive 
cancers such as NSCLC (11). Clinical studies have revealed 
that overexpression of Notch-3 is common in NSCLC and it 
correlates with a shorter progression-free period and shorter 
overall disease-free survival (12). Clinical studies have also 
revealed that a high level of Notch-3 expression is a poor 
prognostic factor for NSCLC (13). Additionally, Notch-3 over-
expression has been reported to be related to the proliferative 
and apoptotic capacity of cancer cells (14). Overall survival is 
?????????????????????????????????????????????????????????????
compared with those with Notch-3-negative tumors (15) and 
high levels of Notch-3 expression have been associated with 
???????????????????????????????????????????????????????????
Notch-3 may be a potential target for cancer therapies, either 
alone or in combination with GEM.
Based on our current understanding of the structure, func-
tion and regulation of the Notch signaling pathway, there 
are several steps which have been identified as potential 
targets for inhibiting this pathway, as well as Notch-3 activity. 
Accumulating evidence has revealed that activation of Notch 
proteins largely depends on ?-secretase activity (18). Thus, 
?-secretase is a promising target for Notch-3 inhibition (19). 
N-[N???????????????????????????????????S-phenylglycine t-butyl 
ester (DAPT) is a ?-secretase that is often referred to as a ‘Notch 
inhibitor’ in oncology. Moreover, DAPT is widely considered 
to act as an inhibitor in terms of biological activity and to 
mediate cytotoxic activities in various types of cancer cells (20). 
In clinical trials, DAPT has had a variety of indications (21). 
To investigate whether DAPT is an effective treatment for 
GEM-resistant tumors, DAPT inhibition of Notch-3 activity was 
tested. DAPT was found to effectively downregulate protein 
levels of NICD3 and to potentially target Notch-3 in gene 
therapy experiments conducted in vitro (22). Therefore, in the 
present study, a combined treatment involving DAPT and GEM 
was examined for its potential to effectively mediate antitumor 
activity in NSCLC cells.
?????????????? ??????
Cell lines. The NSCLC cell lines, H1299 and A549, were 
purchased [American Type Culture Collection (ATCC), 
?????????? ??? ???? ??? ???????? ??????????????? ??????????
???????????????????????????????????????????????????
Scientific, Inc., Shanghai, China) was supplemented with 
????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????
Institute of Biotechnology, Shanghai, China) for each 500 ml 
??????????????????????????????????????????????????????????
incubator containing 5% CO2.
Treatment. DAPT was purchased from Abcam (Shanghai, 
China) (120633) and GEM was a gift from Jiangsu Hansen 
Pharmaceutical Co. Ltd. (Jiangshu, China). The cells in this 
??????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????
?????????? ???????????????????????? ??????????????????
???? ??? ????????? ?????????? ??????? ??????????????? ??? ?? ???
????? ? ??????????????????????????????????????????????
?????????????????????????????? ? ????????????????????????
A549 and H1299 cells, respectively).
Western blot analysis. Cells were plated at 1x105 cells per 
well in 6-well plates and treated as described above. The 
cells were subsequently harvested with lysis buffer (RIPA, 
Beyotime Institute of Biotechnology) and an equal volume 
of 1X SDS buffer (Beyotime Institute of Biotechnology) 
was added to each protein sample. After the samples were 
placed in boiling water for 10 min, they were subsequently 
separated by 10% SDS-polyacrylamide gel electrophoresis 
???????????????????????????????????????????????????????-
lose membranes. The membranes were blocked in Tris-HCl 
buffered saline Tween (TBST) containing 0.5% dry milk and 
then were incubated with antibodies recognizing Notch-3 and 
?????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????
TX, USA), overnight. The membranes were then incubated 
with appropriate goat anti-mouse IgG secondary antibodies 
??????????? ????? ???? ????????? ???????? ?????????? ????????
????????????????????????????????????????????????????????????-
bodies were visualized with enhanced chemiluminescence 
????????????????????????????????????????????????????????
????????? ?????? ???????????????? ?????????????????????????????
???????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????
quantification. Each experiment was repeated 3 times and 
similar results were obtained by the ImageJ bundled with Java 
????????????????????????????????????????
Cultivating higher expression of Notch-3. H1299 and A549 
cells were plated at 1x106 cells per well in 6-well plates. 
Twenty-four hours later, GEM was added to the culture 
medium. After 4 days, both sets of cells were harvested, 
???????????????????????????????????????????????????????????????
detected by western blot analysis. In parallel, an additional set 
of cells from each cell line were cultured with GEM for two 
??????????????????????????????????????????????????????????????
extraction, and expression of Notch-3 was detected by western 
blot analysis. Each experiment was repeated 3 times and 
expression of Notch-3 was compared with and without GEM 
treatment. The cells induced with GEM for two months were 
used in subsequent experiments.
Cell viability assay. Tumor cells were plated in 96-well plates 
with 3,000 cells per well and were allowed to attach overnight. 
To detect the sensitivity of GEM, H1299 and A549 cells were 
incubated with various concentrations of GEM. Different 
concentrations of DAPT were subsequently added to the 
?????????????????????????????????????????????????????????????
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) was added to each well. After 4 h, cell viability for 
each well was measured based on optical density measure-
ments obtained at a wavelength of 490 nm. Each cell viability 
assay was performed six times.
H1299 and A549 cells overexpressing Notch-3 were plated 
in 96-well plates (3,000 cells/well) and were allowed to attach 
??????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????-
?????????????????????????????????????????????????????????
respectively). Two days later, cell viability was evaluated with 
the addition of MTT as described above.
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Apoptosis assay. H1299 and A549 cells overexpressing 
Notch-3 were plated in 6-well plates (1x105 cells/well) and 
were allowed to attach overnight. The cells were then incu-
???????????????????????????????????????????????????????
were treated with GEM at varying concentrations (e.g., H1299 
??????????????????????????????????????????????????????
GEM). Two days later, the cells were trypsinized, collected, 
centrifuged, and washed with pre-cooled phosphate-buffered 
saline (PBS). To each sample (105-106? ?????? ??????? ?? ???
???????? ??????? ?????????? ?????????? ??????? ???? ??? ???
propidium iodide (PI) were added. The samples were mixed 
and then incubated at room temperature in the dark. After 
?????????????????????????????????????????????????????????
(Beckman, USA) within 1 h. The percentages of cells staining 
??????????????????????????????????? ???????????????????????
scripps.edu) and compared. All of these experiments were 
performed in triplicate.
Cell colony assay. H1299 and A549 cells overexpressing 
Notch-3 were seeded in 96-well plates (3,000 cells/well) 
and were allowed to attach overnight. The next day, DMSO 
????????????????????????????????????????????????????????
later, the cells were treated with GEM at varying concentra-
tions. Two days later, the number of colonies that formed 
were counted. After an additional 15 days, the colonies were 
??????? ?????????????? ???????????????????????? ????????????
with hematoxylin for 30 min, and counted. Clusters of cells 
containing >50 cells were scored by fluorescence electron 
microscope (Shanghai Changfang Optical Instrument, Co., 
Ltd., Shanghai, China) as colonies.
Cell count assay. H1299 and A549 cells were cultured in 
24-well plates (104 cells/well). According to the treatment 
?????????????????????????????????????????????????????????
DAPT on the second day after plating. Twenty-four hours 
later, GEM was added. Cells were subsequently counted each 
???????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????
Inc.) to each well. After the cells were detached and dissoci-
?????????????????????????????? ?????? ??????????????????????
digestion. All of the samples were subsequently counted with 
cell counter. Each group was counted 3 times.
??????????????????????????????????????????????????????? ????????????????????????????????????????????????????????????????????????????????????????????????
without treatment with GEM for 4 consecutive days. ?-actin was detected as a loading control. (B) Notch-3 was markedly upregulated after H1299 and A549 
??????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????**P<0.01 vs. 
?????????????????????????????????????????????????????????????
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Sta t is t ica l  analysis.  Data a re  presented as  the 
mean ± standard deviation (SD). Comparisons between 
the treatment groups were performed by applying a t-test. 
???????????????????????????????????????????? ???? ???????
U-test. Values with a P-value <0.05 were considered statisti-
??????????????????*P<0.05, **?????????????????????????????????
???????????????
???????
Induction of Notch-3 overexpression in tumor cells. GEM 
????????????????????????????????????????????????????????????
???????????? ? ????????????????????????????????????????????????
regarding this resistance has been at a nonclinical research 
stage. However, valuable experimental experience has been 
????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
????????????? ???????????????????????? ?????????????????????????????????????????????????? ?????????????? ???????????????????????????????????????????????????
analysis. Experiments were repeated in triplicate. **????????????????????*??????????????????????????????????????????????????????????????????????????????????
?????????????????-secretase inhibitor and indirect inhibitor of Notch.
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gained in the construction of drug-resistant cell models as a 
result of these efforts. Most in vitro studies of NSCLC have 
focused on A549 cells, a human lung adenocarcinoma cell 
line. Here, two commonly used NSCLC cell lines (H1299 and 
A549) were compared, with a focus on Notch-3 protein expres-
sion in response to different durations of GEM induction. In 
?????????????????????????????????????????????????????????????
in protein expression were observed between the no treatment 
group and induction with GEM for 1, 2, 3 and 4 days (Fig. 1A). 
???????????????????????????????????????????????????????????
detected in both cell lines after they were induced with GEM 
for 2 months (Fig. 1B and C). Therefore, H1299 and A549 
??????????????????????????????????????????????????????????????
analyzed in subsequent experiments.
????????????????????????????????????????????????H1299 
and A549 cells overexpressing Notch-3 were incubated with 
???????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????
in NICD3 protein expression. Moreover, marked decreases 
????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????
results suggest that DAPT effectively reduced expression of 
NICD3 (Fig. 2).
Treatment with GEM and DAPT affects cell growth. ?????
A549 and H1299 cells were incubated with GEM, an 
inhibitory effect on cell growth was observed 24, 48 and 
????????????????????????????????????????????????????????????
time-dependent decreases and decreases in the half maximal 
inhibitory concentration (IC50) values for GEM in each cell 
line were observed at the three time points assayed. In cell 
viability assays that were conducted with both cell lines in the 
presence of DAPT and DAPT + GEM, the inhibitory effect of 
GEM was further enhanced compared to the control groups 
at the 48 h time-point (Fig. 3C and D). It is generally believed 
that drug inhibition of tumor cells is related to apoptosis rates 
and colony numbers. Therefore, we subsequently investigated 
the apoptosis rate and colony growth of these 2 cell lines.
DAPT enhances GEM sensitivity to increase apoptosis and 
colony numbers. The percentage of cells undergoing apoptosis 
was significantly increased in both the H1299 and A549 
cells that were treated with DAPT compared with no treat-
ment (Fig. 4A). Moreover, when these two cells lines were 
treated with DAPT + GEM vs. GEM alone, a marked increase 
in the percentage of apoptotic cells was also observed (Fig. 4A). 
Correspondingly, the number of colonies formed following 
treatment of the H1299 and A549 cells with DAPT + GEM 
was markedly lower than the number of colonies formed 
following the treatment of H1299 and A549 cells with GEM 
alone (Fig. 4B and C). These results suggest that DAPT is able 
??????????????????????????????????????????????????????????
consistent with our hypothesis that DAPT enhances the drug 
Figure 3. Notch-3 inactivation promotes GEM-induced cytotoxicity in H1299 and A549 cells. IC50 values for GEM against H1299 and A549 cells at time-points 
??????????????????? ??????????????????????????????????????????????? ??? ?????????????? ??????????????? ???????????????? ??????? ????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
Experiments were performed in triplicate. **?????????????????????????????????????????????-secretase inhibitor and indirect inhibitor of Notch.
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sensitivity of NSCLC cell lines, thereby delaying or blocking 
GEM resistance.
Inhibition of DAPT specifically increases lung cancer 
cell sensitivity to GEM. Cell proliferation was assayed for 
H1299 and A549 cells that were treated with and without 
DAPT and GEM individually and in combination. An 
obvious effect of DAPT on cell proliferation was observed 
in both sets of cells (Fig. 5A and B), while treatment with 
????? ? ??????????????????????????????????????????????
cell proliferation (Fig. 5C and D). These results revealed that 
DAPT positively promoted the pharmacological effects of 
GEM.
Role of apoptosis-related proteins in DAPT-enhanced GEM 
sensitivity. It has been shown that Bcl-2 family proteins can 
be regulated by direct interactions with Bax, Bak, Bcl-2, and 
Bcl-xL to allow mitochondrial outer membrane permeabiliza-
tion (MOMP) and apoptosis to occur. Expression levels of Bcl-2 
and Bax have also been found to be related to GEM resistance. 
Figure 4. Effect of Notch-3 inactivation on GEM-induced apoptosis and colony numbers in NSCLC cell lines. (A) The percentage of apoptotic H1299 and A549 
???????????????????????????????? ?????????? ???????? ????????????????????????????????????????? ????????? ?????????? ?????????????????????????????? ????
???????????????????????????????????????????????????????????????????????**????????????????????*???????????????????????????????????????????????????????
?????????????????????????-secretase inhibitor and indirect inhibitor of Notch.
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Following the treatment of H1299 and A549 cells with GEM, 
Bcl-2 was found to be upregulated, while expression of Bax 
exhibited no obvious changes (Fig. 6A and B). However, when 
these two cell lines were incubated with various concentra-
???????????????????????????????????????????????????????????
Bcl-2 decreased in both cell lines, while expression of Bax 
increased (Fig. 6C-E).
Discussion
To date, there are many methods available that provide inhibi-
tion of Notch signaling pathway activity. Various approaches 
include the targeting of Notch ligands, Notch receptors, 
ADAM-mediated cleavage of Notch, ?-secretase-mediated 
cleavage of Notch, and specific targeting of Notch-3 (19). 
Targeting of Notch-3 by silencing RNA (siRNA) has been 
reported and it is an important method. Moreover, treatment 
with DAPT can decrease cleavage of Notch-3. Direct compari-
sons of Notch-3-targeted siRNAs and DAPT treatments have 
shown that both approaches can achieve a similar silencing 
effect, although other aspects of the Notch signaling pathway 
appear to be affected as well (23).
In the present study, the ?-secretase inhibitor, DAPT, 
was selected to target Notch-3. Our results demonstrated 
that DAPT treatment is able to effectively inhibit NICD3 
?????????????????????????????????????????????????????????????
cell proliferation, with higher concentrations associated with 
stronger inhibitory effects. These results provide evidence 
that DAPT is able to effectively inhibit Notch-3 secretion, 
and Notch-3 is a highly important target for cancer treatment 
as demonstrated in previous studies. Many articles have 
also reported that effective inhibition of Notch-3 activity by 
DAPT results in a decrease in cell proliferation (24). In vivo, 
Tammam et al demonstrated that tumor growth was inhibited 
in a mouse model that received systemic administration of 
DAPT (22). In the present study, DAPT inhibited the prolifera-
????????????????????????????????????????????????????????????????
the percentage of cells undergoing apoptosis, and the numbers 
of colonies formed were decreased. Thus, Notch-3 appears to 
be important for cell viability by promoting cell proliferation 
????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????
studied. Notch-3 has been found to regulate many signaling 
pathways related to tumor development, as well as other impor-
tant proteins in cells, and to promote tumorigenesis or inhibit 
tumor progression (25). Moreover, in our recent clinical study, 
high levels of Notch-3 expression were detected in immunohis-
???????????????????????????? ??????????????????????????????????
factor for NSCLC patients regardless of treatment (26).
In the clinic, chemotherapeutic drugs and molec-
ular-targeted drugs (e.g. inhibitors of EGFR) are used to 
treat NSCLC. However, only a few chemotherapeutic drugs 
are available for long-term treatment of NSCLC due to the 
?????????? ???? ???????????????? ?????? ?????? ?? ????????????
of molecular-targeted drugs and chemotherapy drugs may 
be important for the treatment of cancer. In several clinical 
studies, chemoresistance of NSCLC was found to be related 
to the overexpression of certain proteins, including EGFR, 
Notch and RIPK1 (28-31). It has been recognized that Notch-3 
expression is related to the efficacy of GEM. Moreover, a 
Figure 5. DAPT treatment increased the sensitivity of lung cancer cells to GEM. Cell numbers were reduced after H1299 (A) and A549 (B) cells were treated 
??????????? ???????? ?????????????????????????? ??????????????????????????????????????????????????????????????? ????????????? ???????????????????????
????????????????????????????????????????????????????????-secretase inhibitor and indirect inhibitor of Notch.
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????????????????????????????????????????????????????????????
indeed, high levels of Notch-3 expression have been associ-
ated with resistance to chemotherapy drugs in various types 
of cancers (23,32,33). GEM is used in the clinic due to its 
structural similiarities with deoxycytidine, a molecule which 
affects cells and promotes cell apoptosis. In some clinical 
??????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
H1299 and A549 cells were treated with GEM for two months. (C) Expression levels of Bcl-2 and Bax were detected following treatment of H1299 and A549 
?????? ???????????????????????? ??????????????????????????????????????? ?????????????? ?????????????????????????????????????????????????????????????**P<0.01 
?????????????*?????????????????????????????????????????????-secretase inhibitor and indirect inhibitor of Notch.
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studies of patients with cholangiocarcinoma, overexpression 
of Notch-3 was found to potentially correlate with resistance to 
GEM-based chemotherapy and poor survival (34). Consistent 
with these data, preclinical studies have shown that Notch-3 is 
related to GEM sensitivity in other tumors (30,35). However, 
?????????????? ???????????? ?????????? ???????? ??? ????????
???????????????????????????????????????????????????????????????
???????? ??????????? ??????? ????????????????????? ???????????
is an active area of research. Meanwhile, it is apparent that 
Notch family proteins affect the effectiveness of GEM for 
NSCLC and enhancement of GEM-mediated resistance by 
Notch-3 overexpression has been observed in other types of 
cancer, including pancreatic cancer.
Previously, Aoki et al reported that poor survival was 
associated with Notch-3 expression in cases of extrahepatic 
cholangiocarcinoma (34). The results of the present study 
confirm that cells with long-term exposure to GEM have 
enhanced expression of Notch-3 and increased resistance to 
GEM. There are multiple genes that are involved in mediating 
induced resistance that results from continuous exposure to 
GEM. In the present study, H1299 and A549 cells were exposed 
to GEM to induce overexpression of Notch-3 and to avoid the 
??????????????????????????????????????????????????????????
????? ???????????? ???????????????????? ???????????????????????
effect of GEM in NSCLC cells. Further research is still needed 
to explain how GEM is able to enhance expression of Notch-3 
and suppress secretion of Notch-3 to improve sensitivity to 
GEM chemotherapy. The results of previous studies indicate 
that the process of apoptosis may be involved (36). The results 
of the present study are consistent with this hypothesis, since 
????????????????????????????????????????????????????????
expression, and Bcl-2 expression was also increased. Bcl-2 
???????????????????? ????????????????????????????????????????????
act in mitochondria where the mitochondrial apoptotic 
pathway involves a caspase-9-dependent caspase signaling 
???????????????????????????????????????????????????????????
usually activated by caspase-9 and this leads to the cleavage 
and inactivation of key cellular proteins such as PARP and 
DNA fragmentation factor (38). Some members of the Bcl-2 
family modulate the activation of caspases (39). For example, 
Bcl-2 inhibits the release of cytochrome c by mitochondria, 
thereby preventing cell death (40,41). Therefore, in the present 
study, we focused on Bcl-2 in a preliminary investigation of a 
possible role for apoptosis in GEM resistance. Based on the 
results obtained, further in-depth studies of the mechanistic 
details involved will be pursued.
Thus, further evidence is provided that the drug resistance 
and sensitivity of GEM in relation to Notch-3 involve apoptosis. 
Moreover, support for the inhibition of Notch-3 by DAPT for 
the treatment of patients with NSCLC was demonstrated in the 
present study, especially for patients presenting with resistance 
to GEM. Furthermore, we demonstrated that DAPT could be 
used alone or in combination with GEM.
In summary, Notch-3 is not only important for regu-
lating cell viability, but it is also an important target for 
GEM-mediated antitumor effects. Therefore, Notch-3 may be 
a good candidate for use in the development of new treatment 
strategies for cancer patients who can undergo GEM-based 
chemotherapy and overexpress Notch-3. Furthermore, based on 
the results obtained, a prospective study and clinical treatment 
are under consideration, with the latter including a combined 
treatment region of DAPT and GEM for tumor patients with 
GEM-resistant and Notch-3-overexpressing tumors.
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